{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-000191","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.852405+00:00","generated_at":"2026-05-28T18:09:50.452433+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025","bullets":["IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.","SP-26 ketamine implant for fibromyalgia nearing first animal studies in early 2025; aims for at-home injectable therapeutic.","Both SPC-15 and SP-26 may qualify for FDA's streamlined 505(b)(2) approval pathway, reducing costs and time.","Cash on hand and minimal debt provide financial flexibility; no specific financial guidance disclosed.","Exclusive global license from Columbia University for SPC-15 pre-clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-000191","json":"https://secwatch.observer/filing/0001213900-25-000191.json","markdown":"https://secwatch.observer/filing/0001213900-25-000191.md","text":"https://secwatch.observer/filing/0001213900-25-000191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025000191/0001213900-25-000191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025000191/ea0226314-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T18:09:50.452433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}